+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 18Years - 75Years
All Genders
ID07204275

Adaptive Phase 2b3 Study Comparing Povetacicept and Tacrolimus for Primary Membranous Nephropathy Treatment

Led by Vertex Pharmaceuticals Incorporated · Updated on 2026-10-30

176

Participants Needed

117

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating povetacicept for its efficacy, safety, and tolerability in people with primary membranous nephropathy pMN, a kidney condition. This Phase 2b3 adaptive, randomized study compares povetacicept with the calcineurin inhibitor tacrolimus to determine which treatment better supports clinical remission of pMN. Participants will be randomly assigned to receive one of two doses of povetacicept, given as a subcutaneous injection, or tacrolimus capsules taken orally. The study includes sequential phases, with dosing based on previous phase results. Participants will receive their assigned treatment and be monitored throughout the study. During participation, individuals will be assessed for clinical remission at 104 weeks, and safety will be monitored up to 112 weeks by tracking adverse events. Researchers will conduct regular evaluations to measure how well the treatments work and their tolerability. The total study duration extends up to nearly four years, with ongoing monitoring and data collection.

CONDITIONS

Brief Title

Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

Research Team

M

Medical Information

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here